Show simple item record

dc.contributor.authorBlanchard, Anne
dc.date.accessioned2017-06-12T11:27:49Z
dc.date.available2017-06-12T11:27:49Z
dc.date.issued2016-12
dc.PublishedBlanchard A. Mapping ethical and social aspects of cancer biomarkers. New Biotechnology. 2016;33(6):763-772eng
dc.identifier.issn1871-6784
dc.identifier.urihttps://hdl.handle.net/1956/15964
dc.description.abstractCancer biomarkers represent a revolutionary advance toward personalised cancer treatment, promising therapies that are tailored to subgroups of patients sharing similar generic traits. Notwithstanding the optimism driving this development, biomarkers also present an array of social and ethical questions, as witnessed in sporadic debates across different literatures. This review article seeks to consolidate these debates in a mapping of the complex terrain of ethical and social aspects of cancer biomarker research. This mapping was undertaken from the vantage point offered by a working cancer biomarker research centre called the Centre for Cancer Biomarkers (CCBIO) in Norway, according to a dialectic move between the literature and discussions with researchers and practitioners in the laboratory. Starting in the lab, we found that, with the exception of some classical bioethical dilemmas, researchers regarded many issues relative to the ethos of the biomarker community; how the complexity and uncertainty characterising biomarker research influence their scientific norms of quality. Such challenges to the ethos of cancer research remain largely implicit, outside the scope of formal bioethical enquiry, yet form the basis for other social and ethical issues. Indeed, looking out from the lab we see how questions of complexity, uncertainty and quality contribute to debates around social and global justice; undermining policies for the prioritisation of care, framing the stratification of those patients worthy of treatment, and limiting global access to this highly sophisticated research. We go on to discuss biomarker research within the culturally-constructed ‘war on cancer’ and highlight an important tension between the expectations of ‘magic bullets’ and the complexity and uncertainty faced in the lab. We conclude by arguing, with researchers in the CCBIO, for greater reflexivity and humility in cancer biomarker research and policy.en_US
dc.language.isoengeng
dc.publisherElseviereng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/eng
dc.subjectCancer biomarkerseng
dc.subjectComplexityeng
dc.subjectUncertaintyeng
dc.subjectQualityeng
dc.subjectHumilityeng
dc.titleMapping ethical and social aspects of cancer biomarkerseng
dc.typeJournal articleeng
dc.typePeer reviewedeng
dc.date.updated2017-05-09T07:32:50Z
dc.description.versionpublishedVersion
dc.rights.holderCopyright 2016 The Author(s)eng
dc.identifier.doihttps://doi.org/10.1016/j.nbt.2016.06.1458
dc.identifier.cristin1407894
dc.source.journalNew Biotechnology


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY